J. Kahn

发表

The Science and Business of Genetic Ancestry Testing

P. Ossorio, J. H. Fujimura, R. Cooper, 2007, Science.

Misreading race and genomics after BiDil

J. Kahn, 2005, Nature Genetics.

Translating out of Time: Public Administration and Its History@@@Budgeting Democracy: State Building and Citizenship in America 1890-1928@@@Reinventing Government or Reinventing Ourselves: The Role of Citizen Owners in Making a Better Government

J. Kahn, H. Schachter, C. Stivers, 1999 .

of eliminating racial/ethnic disparities in health care.

J. Kahn, P. Sankar, 2005 .

The OHRP and SUPPORT--another view.

Ellen K. Feder, A. Silvers, C. Elliott, 2013, The New England journal of medicine.

Being Specific About Race-Specific Medicine

J. Kahn, P. Sankar, 2006, Health affairs.

Perspective Being Specific About Race-Specific Medicine

J. Kahn, P. Sankar, 2006 .

BiDil's Interim Model of Pharmacogenomics

J. Kahn, 2008 .

Pills for Prejudice: Implicit Bias and Technical Fix for Racism

J. Kahn, 2017, American Journal of Law & Medicine.

7. Bidil and Racialized Medicine

J. Kahn, 2011 .

Patenting Race in a Genomic Age1

J. Kahn, 2008, Genomics, society, and policy.

Race, Pharmacogenomics, and Marketing: Putting BiDil in Context

J. Kahn, 2006, The American journal of bioethics : AJOB.

Pharmacogenetics and ethnically targeted therapies

J. Kahn, 2005, BMJ : British Medical Journal.

48. The Science and Business of Genetic Ancestry Testing

P. Ossorio, J. H. Fujimura, J. Kaufman, 2019, Beyond Bioethics.

BiDil: race medicine or race marketing?

J. Kahn, P. Sankar, 2005, Health affairs.

Harmonizing Race: Competing Regulatory Paradigms of Racial Categorization in International Drug Development

J. Kahn, 2007 .

Budgeting Democracy: State Building and Citizenship in America, 1890-1928

J. Kahn, 1997 .

Genes, Race, and Population: Avoiding a Collision of Categories

J. Kahn, 2006, American journal of public health.

"Ethnic Drugs"

J. Kahn, 2005, The Hastings Center report.

Race and ancestry in biomedical research: exploring the challenges

S. Scherer, S. Fullerton, R. Kittles, 2009, Genome Medicine.

Perspective: "Ethnic Drugs"

J. Kahn, 2005 .

Race in a Bottle: The Story of BiDil and Racialized Medicine in a Post-Genomic Age

J. Kahn, 2012 .

Race, Genes, and Justice: A Call to Reform the Presentation of Forensic DNA Evidence in Criminal Trials.

J. Kahn, 2009, Brooklyn law review.

Race-ing Patents/Patenting Race: An Emerging Political Geography of Intellectual Property in Biotechnology

J. Kahn, 2007 .

From Disparity to Difference: How Race-Specific Medicines May Undermine Policies to Address Inequalities in Health Care

J. Kahn, 2006, Southern California interdisciplinary law journal.

How a drug becomes "ethnic": law, commerce, and the production of racial categories in medicine.

J. Kahn, 2004, Yale journal of health policy, law, and ethics.

Mandating race: how the USPTO is forcing race into biotech patents

J. Kahn, 2011, Nature Biotechnology.

Race in a Bottle

J. Kahn, 2007 .

'When are you from?' Time, space, and capital in the molecular reinscription of race.

J. Kahn, 2015, The British journal of sociology.

Enslaving the Image: The Origins of the Tort of Appropriation of Identity Reconsidered

J. Kahn, 1996, Legal Theory.

In the Wake of Terror: Medicine and Morality in a Time of Crisis

J. Kahn, 2004 .

Biotechnology and the legal constitution of the self: managing identity in science, the market, and society.

J. Kahn, 2000, Hastings Law Journal.

The Two (Institutional) Cultures: A Consideration of Structural Barriers to Interdisciplinarity

J. Kahn, 2011, Perspectives in biology and medicine.

Getting the Numbers Right: Statistical Mischief and Racial Profiling in Heart Failure Research

J. Kahn, 2003, Perspectives in biology and medicine.

The Troubling Persistence of Race in Pharmacogenomics

J. Kahn, 2012, Journal of Law, Medicine & Ethics.

Beyond BiDil: the Expanding Embrace of Race in Biomedical Research and Product Development

J. Kahn, 2010 .

Surrogate Markers and Surrogate Marketing in Biomedicine: The Regulatory Etiology and Commercial Progression of “Ethnic” Drug Development

J. Kahn, 2009 .

DIME Working Papers on INTELLECTUAL PROPERTY RIGHTS

J. Kahn, 2006 .

What's in a Name? Law's Identity Under the Tort of Appropriation

J. Kahn, 2001 .

Exploiting Race in Drug Development

J. Kahn, 2008, Social studies of science.

Mapping "Race"

J. Kahn, Aliya Saperstein, Nancy López, 2013 .

The Troubling Persistence of Race in Pharmacogenomics

J. Kahn, 2012, Journal of Law, Medicine & Ethics.

Flaws in the U.S. Food and Drug Administration's Rationale for Supporting the Development and Approval of BiDil as a Treatment for Heart Failure Only in Black Patients

J. Kaufman, Paul Martin, J. Kahn, 2008, Journal of Law, Medicine & Ethics.

BiDil for heart failure in black patients.

J. Kahn, 2007, Annals of internal medicine.